India hands over vaccine against Sickle Cell and Thalassemia to Nepal
Kathmandu: In a significant demonstration of its ongoing commitment to supporting the health and well-being of the people of Nepal, Ambassador of India to Nepal, Naveen Srivastava handed over the first consignment of vaccines for Sickle Cell Disease and Thalassemia to Minister of Health and Population, of Nepal, Pradip Paudel.
As per the release from the Indian Embassy in Kathmandu the first consignment of vaccines is worth USD 2 million. It would be for the management of patients with Thalassemia and Sickle Cell Disease responding to a request from Nepal.
"The first consignment of vaccines/ medicines includes Influenzae Vaccine (3100 unit), Salmonella Vaccine (1550 unit), Meningococcus Vaccine (3100 unit), Haemophilus Influenza Vaccine (4640 unit) and Streptococcus Pneumonia Vaccine (4640 unit)," the release detailed.
This vital contribution from India will help bolster Nepal's efforts in addressing these inherited blood disorders, which pose significant health challenges to affected individuals and families.
"The provision of these vaccines underscores the strong and enduring partnership between the two nations, particularly in the crucial healthcare sector," the embassy highlighted.
Speaking at the handover event, the Indian Ambassador noted that these vaccines would be instrumental in enhancing the quality of life for individuals affected by Sickle Cell Disease and Thalassemia in Nepal.
He further mentioned the deep-rooted friendship between India and Nepal and India's readiness to extend support in areas of mutual interest.
Receiving the vaccines on behalf of the Government of Nepal, Minister of Health and Population expressed gratitude for India's generous support outlining the positive impact these vaccines will have on public health. Paudel acknowledged the long-standing collaboration with India and its contributions to Nepal's healthcare system.
"This initiative is a testament to the close ties and collaborative spirit between India and Nepal, reflecting a shared vision for a healthier future for their citizens," the release stated.
Furthermore, the India also has committed to partnering with Nepal in various sectors, including health, to foster mutual progress and development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times of Oman
21-05-2025
- Times of Oman
India, Nepal strengthen health cooperation at WHA78 bilateral meeting in Geneva
Geneva: Reinforcing the strong health partnership between the two nations, India and Nepal held a significant bilateral meeting in Geneva on Tuesday on the sidelines of the 78th World Health Assembly (WHA78). The meeting, held between India's Health Secretary Punya Salila Srivastava and Nepal's Minister of Health and Population Pradip Paudel, focused on key health issues such as affordable drugs, communicable and non-communicable diseases (NCDs), digital health, and capacity building of the health workforce. "A bilateral meeting took place today on the sidelines of #WHA78 between Health Secretary, Govt of India, Punya Salila Srivastava and Pradip Paudel, Minister of Health and Population, Govt of Nepal. Bilateral issues on health such as ensuring affordable drugs, communicable diseases, NCDs, digital health and capacity building of health workforce were discussed," the Ministry of Health and Family Welfare (MoHFW) stated in a post on X. "The meeting also reinforced the strong partnership and support shared by India and Nepal," The MoHFW further noted. Earlier, India was conferred with the certificate of eliminating Trachoma as a public health problem at the 78th World Health Assembly in Geneva. Union Health Minister JP Nadda lauded this achievement and said it was a proud moment for the nation. "A proud moment for the nation at WHA78 (World Health Assembly), India has been conferred the Certificate of Elimination of Trachoma as a Public Health Problem by Tedros Adhanom Ghebreyesus, Director-General at WHO, at the 78th World Health Assembly in Geneva," Nadda stated in a post on X. Meanwhile, Prime Minister Narendra Modi virtually addressed the 78th Session of the World Health Assembly in Geneva from New Delhi on Tuesday, highlighting India's contributions to global health initiatives under the unifying theme of "One World for Health". PM Modi mentioned India's Ayushman Bharat scheme, the world's largest health insurance programme, which covers 580 million people and provides free treatment. He outlined three cores for the future of a healthy world - inclusion, integrated vision and collaboration.
Times of Oman
20-05-2025
- Times of Oman
India sends delegation to 78th World Health Assembly, reaffirms commitment to global health cooperation
Geneva: Reaffirming its commitment towards global health cooperation, India has sent a delegation to participate in the 78th World Health Assembly commencing in Geneva, the Ministry of Health and Family Welfare (MoHFW), shared on Monday. Providing the details in a post on X, the MoHFW said that the Indian delegation is being led by Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare. It further noted that India's participation reflects the continued commitment towards strengthening global health systems and advancing international collaboration. "Today marks the commencement of the 78th World Health Assembly in Geneva. The Indian delegation, led by Ms. Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare, Government of India, is actively participating in the Assembly, reflecting India's continued commitment to strengthening global health systems and advancing international collaboration." As per the World Health Organisation, the 78th World Health Assembly is being held in Geneva from May 19-27. The theme of this year's Health Assembly is, "One World for Health." Notable highlights from the 78th Session would include, May 19 that marks the opening og the Assembly, with deliberations on the Pandemic Agreement in the afternoon. On May 20, it is expected that the adoption of the Pandemic Agreement would take place along with a discussion on the Proposed Programme Budget 2026-2027. May 21 would see a Ministerial Roundtable on data and sustainable financing and May 23 would see the presentation of the public health prizes and awards, the details were shared by WHO in an earlier post on X. The most recent update has been the election of Dr Teodoro Javier Herbosa from the Philippines as President of the 78th World Health Assembly. At the World health assemsbly, member States and the WHO Secretariat will have to reconcile a significant funding shortfall ahead of the next two-year programme budget. While fully funding WHO's growing mandate of work has long faced challenges, the United States' intended withdrawal from the Organization has further strained the budget. A planned 20% increase in mandatory member contributions that was years in the making will be up for adoption at WHA78, offering a potential boost--but in a constrained fiscal climate, its approval is uncertain. Broader governance and staffing reforms will also be on the agenda.
Times of Oman
06-05-2025
- Times of Oman
India pioneers gene therapy breakthrough for Haemophilia at Bengaluru's BRIC-inStem
India has long stood at the forefront of healthcare innovation, and recent advances in biotechnology have further solidified its position as a global leader in medical science. Among the most notable breakthroughs in recent years is a pioneering achievement from Bengaluru's BRIC-inStem—the Biotechnology Research and Innovation Centre in collaboration with the Institute for Stem Cell Biology and Regenerative Medicine. This institution has led a major leap in India's bio-revolution through its development of gene therapy for haemophilia, a genetic bleeding disorder that has posed longstanding challenges to treatment, Indian media reports. Addressing a Lifelong Disorder Haemophilia is a rare inherited condition that impairs the body's ability to form blood clots, resulting in spontaneous or prolonged bleeding episodes. Conventional treatments, such as regular infusions of clotting factors, have been used to manage the disease. However, these treatments are costly, require lifelong administration, and may not be readily accessible in all regions. Now, thanks to advanced research at BRIC-inStem, gene therapy is offering hope—not merely for symptom management, but for a potential cure. By delivering a functional copy of the defective clotting factor gene directly into the patient's body, this therapy targets the root cause of haemophilia. It enables the patient to naturally produce clotting factors, potentially reducing or eliminating the need for repeated infusions. BRIC-inStem: At the Heart of India's Biotechnology Revolution Bengaluru, widely known as the 'Silicon Valley of India,' is fast becoming the nucleus of the country's biotechnology transformation. At the center of this shift is BRIC-inStem, an institution driving innovation in gene therapy, stem cell biology, and regenerative medicine. Established to address some of the world's most pressing medical challenges, BRIC-inStem has evolved into a hub for breakthrough therapies. With contributions from top scientists, clinicians, and biotech innovators, BRIC-inStem is spearheading a transformative era in Indian healthcare. Its recent success in developing gene therapy for haemophilia underscores the growing strength and international relevance of India's biotech sector. By tackling complex genetic disorders with cutting-edge treatments, the institute is positioning India as a global trailblazer in life sciences. Transforming Haemophilia Treatment The gene therapy developed by BRIC-inStem involves the delivery of a healthy version of the clotting factor gene into patients. This innovative approach not only corrects the genetic defect but offers the possibility of a long-term solution to a condition that previously required lifelong management. Crucially, the research is being conducted in collaboration with leading Indian medical institutions, ensuring that the benefits of this breakthrough are accessible to the patients who need them most. The therapy has demonstrated both high efficacy and safety, representing a major step forward in haemophilia care. What makes this development particularly impactful is its potential scalability. In a country like India, where genetic disorders are prevalent and access to continuous care can be limited, a one-time or long-term therapeutic intervention could revolutionize patient outcomes. It could significantly reduce healthcare costs, improve patient quality of life, and alleviate the socioeconomic burdens associated with chronic illness. Expanding Frontiers in Regenerative Medicine BRIC-inStem's contributions are not limited to gene therapy. The institute is also advancing the field of regenerative medicine—an area focused on repairing or replacing damaged tissues and organs through the body's natural healing processes. This is especially critical for conditions that lack effective treatments through traditional methods. Through pioneering work in stem cell research and tissue engineering, BRIC-inStem is developing therapies that could one day replace failing organs, treat degenerative diseases, and repair complex injuries such as spinal cord damage. These advancements represent the convergence of biotechnology and personalized medicine, where innovative science enhances the body's own capacity to heal. When combined with gene therapy, regenerative medicine offers a vision of healthcare that is not just reactive, but restorative—one where conditions once deemed incurable are addressed at their biological roots. India's Global Role in Biotech Innovation With BRIC-inStem at the forefront, India is asserting its role as a global force in biotechnology. The country's rapidly maturing biotech ecosystem is characterized by world-class research, cross-sector collaboration, and a focus on scalable, affordable healthcare solutions. India's approach—developing cutting-edge therapies that are also accessible—sets it apart from many Western counterparts. In contrast to high-cost models that often limit patient access, India is creating therapies that can be deployed at population scale. This is especially critical given the high incidence of genetic disorders within the country and the urgent need for equitable healthcare solutions. BRIC-inStem's achievements exemplify this approach, showcasing how India is not only contributing to global science but doing so in a way that prioritizes public health impact. A New Dawn for Haemophilia Patients The implications of BRIC-inStem's work in gene therapy for haemophilia are profound. For patients who have long lived under the constraints of chronic treatment, the promise of a durable or permanent solution signals a transformative shift in care. Beyond reducing hospital visits and medical expenses, gene therapy offers a future in which individuals with haemophilia can enjoy greater freedom, improved health, and enhanced participation in daily life. It marks a shift from disease management to potential cure—a leap that redefines what is possible in genetic medicine. This accomplishment also serves as a foundation for broader innovation. It demonstrates that India is not only capable of pioneering high-impact research, but also translating it into treatments that change lives. Looking Ahead: A Bright Future for Indian Biotech As BRIC-inStem continues to lead in gene therapy and regenerative science, the future of Indian biotechnology looks exceptionally promising. With a focus on translational research, global collaboration, and patient-centric outcomes, India is poised to become a key driver of the next generation of medical breakthroughs. The successful development of gene therapy for haemophilia is just the beginning. With continued investment, support, and innovation, India is on track to reshape the global healthcare landscape—delivering hope, healing, and progress to millions. Bengaluru's BRIC-inStem stands as a beacon of this progress, exemplifying how science, when backed by vision and commitment, can transform the future of medicine not just in India, but around the world.
